Vascular cognitive impairment: current concepts and clinical developments

Paige Moorhouse; Kenneth Rockwood

doi:10.1016/S1474-4422(08)70040-1

Vascular cognitive impairment: current concepts and clinical developments

Paige Moorhouse, Kenneth Rockwood

Research output: Contribution to journal › Review article › peer-review

289 Citations (Scopus)

Abstract

Vascular cognitive impairment (VCI) comprises a range of cognitive disorders related to cerebral vessel disease and has generally replaced the term multi-infarct dementia. Despite the heterogeneity of the VCI construct, some clinical patterns can be discerned, which enable subtypes, such as mixed dementia and VCI-no dementia, to be recognised. Diagnostic criteria for vascular dementia do not encompass the full range of the VCI construct, and clinical investigators now recognise the need for harmonised standards to study the many manifestations of VCI seen in daily practice and to inform the development of diagnostic criteria. Although executive dysfunction is a recognised feature of VCI, some data suggest a less exclusive role than was previously proposed. VCI might be preventable, although the evidence for this is not as complete as it is for the prevention of stroke. Future studies into specific therapies for VCI will need to consider the clinical features and outcomes carefully.

Original language	English
Pages (from-to)	246-255
Number of pages	10
Journal	The Lancet Neurology
Volume	7
Issue number	3
DOIs	https://doi.org/10.1016/S1474-4422(08)70040-1
Publication status	Published - Mar 2008
Externally published	Yes

Bibliographical note

Funding Information:
Kenneth Rockwood is supported by the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research. Paige Moorhouse receives career support, in part, from the Fountain Innovation Fund of the QE-II Foundation, capital health, Halifax.

Funding Information:
KR has received speaking and consulting fees from GlaxoSmithKline, Janssen Ortho, Lundbeck, Merck, Myriad, Novartis, Numico, and Pfizer, and he holds a research grant from Janssen through the Canadian Institutes of Health Research and Development program. Each of those companies develops compounds that affects cognition. KR is also founder and president of DementiaGuide, Inc, a web-based company that offers information about the symptoms of dementia and the response to treatment.

ASJC Scopus Subject Areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(08)70040-1

Cite this

Moorhouse, P., & Rockwood, K. (2008). Vascular cognitive impairment: current concepts and clinical developments. The Lancet Neurology, 7(3), 246-255. https://doi.org/10.1016/S1474-4422(08)70040-1

@article{9caadb947c2a46b6b5f86bad6dce389c,

title = "Vascular cognitive impairment: current concepts and clinical developments",

abstract = "Vascular cognitive impairment (VCI) comprises a range of cognitive disorders related to cerebral vessel disease and has generally replaced the term multi-infarct dementia. Despite the heterogeneity of the VCI construct, some clinical patterns can be discerned, which enable subtypes, such as mixed dementia and VCI-no dementia, to be recognised. Diagnostic criteria for vascular dementia do not encompass the full range of the VCI construct, and clinical investigators now recognise the need for harmonised standards to study the many manifestations of VCI seen in daily practice and to inform the development of diagnostic criteria. Although executive dysfunction is a recognised feature of VCI, some data suggest a less exclusive role than was previously proposed. VCI might be preventable, although the evidence for this is not as complete as it is for the prevention of stroke. Future studies into specific therapies for VCI will need to consider the clinical features and outcomes carefully.",

author = "Paige Moorhouse and Kenneth Rockwood",

note = "Funding Information: Kenneth Rockwood is supported by the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research. Paige Moorhouse receives career support, in part, from the Fountain Innovation Fund of the QE-II Foundation, capital health, Halifax. Funding Information: KR has received speaking and consulting fees from GlaxoSmithKline, Janssen Ortho, Lundbeck, Merck, Myriad, Novartis, Numico, and Pfizer, and he holds a research grant from Janssen through the Canadian Institutes of Health Research and Development program. Each of those companies develops compounds that affects cognition. KR is also founder and president of DementiaGuide, Inc, a web-based company that offers information about the symptoms of dementia and the response to treatment. ",

year = "2008",

month = mar,

doi = "10.1016/S1474-4422(08)70040-1",

language = "English",

volume = "7",

pages = "246--255",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - Vascular cognitive impairment

T2 - current concepts and clinical developments

AU - Moorhouse, Paige

AU - Rockwood, Kenneth

N1 - Funding Information: Kenneth Rockwood is supported by the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research. Paige Moorhouse receives career support, in part, from the Fountain Innovation Fund of the QE-II Foundation, capital health, Halifax. Funding Information: KR has received speaking and consulting fees from GlaxoSmithKline, Janssen Ortho, Lundbeck, Merck, Myriad, Novartis, Numico, and Pfizer, and he holds a research grant from Janssen through the Canadian Institutes of Health Research and Development program. Each of those companies develops compounds that affects cognition. KR is also founder and president of DementiaGuide, Inc, a web-based company that offers information about the symptoms of dementia and the response to treatment.

PY - 2008/3

Y1 - 2008/3

N2 - Vascular cognitive impairment (VCI) comprises a range of cognitive disorders related to cerebral vessel disease and has generally replaced the term multi-infarct dementia. Despite the heterogeneity of the VCI construct, some clinical patterns can be discerned, which enable subtypes, such as mixed dementia and VCI-no dementia, to be recognised. Diagnostic criteria for vascular dementia do not encompass the full range of the VCI construct, and clinical investigators now recognise the need for harmonised standards to study the many manifestations of VCI seen in daily practice and to inform the development of diagnostic criteria. Although executive dysfunction is a recognised feature of VCI, some data suggest a less exclusive role than was previously proposed. VCI might be preventable, although the evidence for this is not as complete as it is for the prevention of stroke. Future studies into specific therapies for VCI will need to consider the clinical features and outcomes carefully.

AB - Vascular cognitive impairment (VCI) comprises a range of cognitive disorders related to cerebral vessel disease and has generally replaced the term multi-infarct dementia. Despite the heterogeneity of the VCI construct, some clinical patterns can be discerned, which enable subtypes, such as mixed dementia and VCI-no dementia, to be recognised. Diagnostic criteria for vascular dementia do not encompass the full range of the VCI construct, and clinical investigators now recognise the need for harmonised standards to study the many manifestations of VCI seen in daily practice and to inform the development of diagnostic criteria. Although executive dysfunction is a recognised feature of VCI, some data suggest a less exclusive role than was previously proposed. VCI might be preventable, although the evidence for this is not as complete as it is for the prevention of stroke. Future studies into specific therapies for VCI will need to consider the clinical features and outcomes carefully.

UR - http://www.scopus.com/inward/record.url?scp=38949100728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949100728&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(08)70040-1

DO - 10.1016/S1474-4422(08)70040-1

M3 - Review article

C2 - 18275926

AN - SCOPUS:38949100728

SN - 1474-4422

VL - 7

SP - 246

EP - 255

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 3

ER -

Vascular cognitive impairment: current concepts and clinical developments

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this